RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Multiple System Atrophy: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Automated differentiation for parkinsonism using clinical structural MRI: A multicenter study
周立彻 et al., npj Digital Medicine (16 October 2026)
https://doi.org/10.1038/s41746-026-03357-z
- 2.
Association of visually assessed putaminal and infratentorial MRI signs with motor symptoms in multiple system atrophy: a cross-sectional study
Kai Li et al., BMC Medical Imaging (16 October 2026)
https://doi.org/10.1186/s12880-026-02958-0
- 3.
Involuntary inspiratory sigh in multiple system atrophy: A clinical and cerebral blood flow study.
Nakagawa Yuki et al., Journal of the neurological sciences (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42476092/
- 4.
Diagnostic value of susceptibility-based imaging and apparent diffusion coefficient for differentiating multiple system atrophy-Parkinsonian type from Parkinson's disease
Byeongpil Moon et al., Frontiers in Aging Neuroscience (14 October 2026)
https://doi.org/10.3389/fnagi.2026.1967702
- 5.
Accuracy of Machine Learning in Differential Diagnosis of Multiple System Atrophy: A Systematic Review and Meta-Analysis.
Wang Guisheng et al., Movement disorders clinical practice (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42872575/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
NCT06706622 · Active (not recruiting) · Phase 3 · H. Lundbeck A/S
Ages 40 to 75
https://clinicaltrials.gov/study/NCT06706622
- 2.
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717 · Active (not recruiting) · Phase 3 · Theravance Biopharma
Ages 30 and over
https://clinicaltrials.gov/study/NCT05696717
- 3.
Study of ATH434 in Participants with Multiple System Atrophy
NCT05109091 · Completed · Phase 2 · Alterity Therapeutics
Ages 30 to 75
https://clinicaltrials.gov/study/NCT05109091
- 4.
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
NCT00738062 · Completed · Phase 3 · Chelsea Therapeutics
Ages 18 and over
https://clinicaltrials.gov/study/NCT00738062
- 5.
Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy
NCT00103597 · Completed · Phase 1 · Royal Brisbane and Women's Hospital
Ages 40 to 95
https://clinicaltrials.gov/study/NCT00103597
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Multiple System Atrophy
Multiple System Atrophy is a rare and fatal neurodegenerative disease that affects movement, balance, and the autonomic nervous system. It is characterised by alpha-synuclein deposits in glial cells. MSA progresses faster than Parkinson's disease, with median survival of 6-10 years from symptom onset. Diagnosis is challenging and often delayed.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Multimodal research-grade magnetic resonance imaging (MRI) scans show potential for differentiating Parkinson’s disease (PD) from multiple system atrophy (MSA), but clinical translation is limited by cost, acquisition time, and processing burden. Here, we developed a T1-weighted structural MRI-based machine learning model to differentiate Parkinsonism and generalized it to routine anisotropic 2D clinical MRI. Using a multicenter cohort of 969 participants, we employed a hierarchical discovery–verification–translation framework. While a multimodal benchmark model achieved an area under the receiver operating characteristic curve (AUROC) of 0.98, our streamlined unimodal T1-Top20 model achieved an AUROC of 0.93 for multiclass discrimination (healthy controls, PD, MSA). For PD vs MSA, the frozen T1-Top20 model achieved a pooled AUROC of 0.88 in the external research-grade cohort ( n = 227) and identified 19 of 25 who phenoconverted from idiopathic rapid eye movement sleep behavior disorder (iRBD) to PD. Importantly, the generalized model achieved a pooled AUROC of 0.84 in the clinical-MRI cohort (2D T1, n = 303), supporting its potential for clinical translation.
Common Questions
What is Multiple System Atrophy?
Multiple System Atrophy is a rare and fatal neurodegenerative disease that affects movement, balance, and the autonomic nervous system. It is characterised by alpha-synuclein deposits in glial cells. MSA progresses faster than Parkinson's disease, with median survival of 6-10 years from symptom onset. Diagnosis is challenging and often delayed.
How many clinical trials are available for Multiple System Atrophy?
RareWays currently indexes 139 clinical trials for Multiple System Atrophy, of which 34 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Multiple System Atrophy come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Multiple System Atrophy.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.